Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

The National Comprehensive Cancer Network (NCCN).

Elizabeth H. Wood · Europe PMC (PubMed Central) · 2004 · 2.9K citations · Full text

Medicine, Oncology, Cancer Prevention +12

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation

Richard M. Stone, Sumithra J. Mandrekar, Ben L. Sanford et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

Medicine, Molecular Medicine, Pharmacotherapy +16

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

Jay P. Patel, Mithat Gönen, María E. Figueroa et al. · New England Journal of Medicine · 2012 · 1.9K citations · Full text

Life Sciences, Genetics, Oncology +16

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

Nicole M. Kuderer, David C. Dale, Jeffrey Crawford et al. · Cancer · 2006 · 1.2K citations · Full text

Medicine, Oncology, Cancer Control +6

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm

Stefan Fröhling, Richard F. Schlenk, Jochen Breitruck et al. · Blood · 2002 · 866 citations

Life Sciences, Genetics, Hematology +16